Skip to main navigation
  • Home

  • Menu

Main menu

  • About Mersana
  • Our Technology
  • Pipeline
  • Partners
  • Investors & Media
    • Overview
    • Stock Information
    • Analyst Coverage
    • SEC Filings
    • Press Releases
    • Events & Presentations
    • Scientific Publications
    • Corporate Governance
    • Investor FAQs
    • Contact Us
  • Join Our Team
    • #MyMersana
    • Careers

Investors & Media

Press Releases
  • Overview
  • Stock Information
  • Analyst Coverage
  • SEC Filings
  • Press Releases
  • Events & Presentations
  • Scientific Publications
  • Corporate Governance
  • Investor FAQs
  • Contact Us
  • All Releases
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • March 1, 2019
    Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2018 Financial Results and Business Updates
    PDF Version
  • March 1, 2019
    Mersana Therapeutics Announces Pricing of Public Offering of Common Stock
    PDF Version
  • February 28, 2019
    Mersana Therapeutics Announces Proposed Public Offering of Common Stock
    PDF Version
  • February 20, 2019
    Mersana Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
    PDF Version
  • January 4, 2019
    Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond
    PDF Version
  • January 2, 2019
    Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
    PDF Version
  • November 27, 2018
    Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
    PDF Version
  • November 13, 2018
    Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
    PDF Version
  • November 12, 2018
    Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
    PDF Version
  • November 12, 2018
    Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
    PDF Version

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page Next
  • Last page Last
Displaying 21 - 30 of 122 results
  • Email Alerts
  • Contact Us
  • RSS Feeds
  • Print Page
  • Email Page

Mersana Therapeutics
840 Memorial Drive
Cambridge, MA 02139

info@mersana.com

617.498.0020

  • Careers
  • Contact
  • Terms of Use
  • Privacy Policy

© 2019 Mersana Therapeutics, All Rights Reserved.